The dominant neurobiological model of Attention-Deficit/Hyperactivity Disorder (ADHD) frames the condition as a problem of dopamine dysregulation. This paper argues that this framing is wrong, and that the primary deficit in ADHD lies upstream in the cholinergic system, specifically in the insufficient production of acetylcholine, which cascades into receptor loss during development, dopaminergic irregularity as a downstream consequence, and the full clinical picture of the disorder. The argument rests on several converging lines of evidence and logic: bupropion, a dopamine reuptake inhibitor producing 20% transporter blockade sufficient to treat suicidal depression, fails meaningfully in ADHD implying dopamine baseline is not the problem; cholinergic reuptake inhibitors similarly fail, but for the opposite reason not because more acetylcholine is dangerous at baseline but because there was too little to begin with, and slowing its removal does not help when the production tap is barely running; independent studies find approximately 50% reduced muscarinic receptor density in ADHD populations; animal models show that removing a single muscarinic receptor subtype reproduces the ADHD phenotype; and nicotine, which bypasses the entire broken production chain by acting directly at the receptor, improves attention in clinical trials without the motivational flooding of stimulants. Beyond pharmacology, the paper proposes that ADHD is better understood as a natural population variation in cholinergic baseline rather than a discrete disorder, that the anterior mid-cingulate cortex evolved as a willpower override specifically to compensate for this variation, that modern environments have eroded the developmental conditions that historically built this compensation automatically, and that rising ADHD prevalence reflects an environmental and developmental failure more than a neurological epidemic. Rejection Sensitive Dysphoria, hyperfocus, deadline productivity through adrenergic emergency pathways, and emotional amplification are all explained as direct expressions of the same primary cholinergic deficit. Transdermal nicotine replacement therapy is proposed as the mechanistically appropriate treatment. Testable predictions are offered.
Rajat Bharti (Thu,) studied this question.